Argentina approves Harpin as seed treatment in Corn and Soybeans
LONDON, UK: Plant Health Care, a leading provider of novel patent-protected biological products to global agriculture markets, announced the registration approval of Harpin ab for use as a seed treatment of corn and soybeans in Argentina.
The regulatory process in Argentina for agricultural products involves detailed review and approval by Senasa, the Country’s National Food Safety and Quality Service, which classified Harpin ab as a biostimulant organic-chemical fertilizer. This confirms the Argentinian government’s commitment to promoting cost effective, sustainable and safe products.
Highlights
· Corn and soybeans are the first crops to receive regulatory approval for Harpin ab in Argentina.
· Argentina has 24 million hectares (60 million acres) of corn and soybeans planted in the current season. Growers spent more than $100m on soybean seed treatments in Argentina in the most recent season. The size of the biological market in soybeans is growing rapidly and was about $75m in 2021.
· The Company is currently working with multiple organizations that are evaluating Harpin ab and will select in-country distribution partners in due course.
Harpin ab works by triggering the plant’s own self defense systems, leading to a robust physiological response, in a manner similar to vaccinations in humans. The plant responds with improved crop quality, nutrient use efficiency, tolerance to abiotic stress and ultimately, increased yield. Being a biological product, Harpin αβ has a very favorable human and environmental safety profile.
Chris Richards, CEO of Plant Health Care, said: ‟Harpin ab registration in Argentina is key to the further expansion of Harpin ab use into large row crop markets.”
Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables.
Plant Health Care plc share price
13.44 GBX+0.69 (5.41%)today
1 Sep, 8:01 am GMT+1 ·Disclaimer
About The Author
